A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Ziyue Wang, Adam Cryar, Oliver Lemke, Daniela Ludwig, Pinkus Tober-Lau, Elisa Theresa Helbig, Daniel Blake, Catherine S Lane, Rebekah L Sayers, Christoph Mueller, Johannes Zeiser, StJohn Townsend, Vadim Demichev, Michael Mülleder, View ORCID ProfileFlorian Kurth, View ORCID ProfileErnestas Sirka, View ORCID ProfileJohannes Hartl, View ORCID ProfileMarkus Ralser
doi: https://doi.org/10.1101/2021.12.03.21267253
Ziyue Wang
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Adam Cryar
2Inoviv, London, United Kingdom
Oliver Lemke
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Daniela Ludwig
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Pinkus Tober-Lau
3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Elisa Theresa Helbig
3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Daniel Blake
4SCIEX, Macclesfield, United Kingdom
Catherine S Lane
4SCIEX, Macclesfield, United Kingdom
Rebekah L Sayers
4SCIEX, Macclesfield, United Kingdom
Christoph Mueller
5Agilent Technologies Sales & Services GmbH & Co. KG, Waldbronn, Germany
Johannes Zeiser
5Agilent Technologies Sales & Services GmbH & Co. KG, Waldbronn, Germany
StJohn Townsend
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Vadim Demichev
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Michael Mülleder
6Core Facility – High-Throughput Mass Spectrometry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility – High-Throughput Mass Spectrometry, Am Chariteplatz 1, Berlin, Germany
Florian Kurth
3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
7Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Ernestas Sirka
2Inoviv, London, United Kingdom
Johannes Hartl
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Markus Ralser
1Department of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Am Chariteplatz 1, Berlin, Germany
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted December 05, 2021.
A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Ziyue Wang, Adam Cryar, Oliver Lemke, Daniela Ludwig, Pinkus Tober-Lau, Elisa Theresa Helbig, Daniel Blake, Catherine S Lane, Rebekah L Sayers, Christoph Mueller, Johannes Zeiser, StJohn Townsend, Vadim Demichev, Michael Mülleder, Florian Kurth, Ernestas Sirka, Johannes Hartl, Markus Ralser
medRxiv 2021.12.03.21267253; doi: https://doi.org/10.1101/2021.12.03.21267253
A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Ziyue Wang, Adam Cryar, Oliver Lemke, Daniela Ludwig, Pinkus Tober-Lau, Elisa Theresa Helbig, Daniel Blake, Catherine S Lane, Rebekah L Sayers, Christoph Mueller, Johannes Zeiser, StJohn Townsend, Vadim Demichev, Michael Mülleder, Florian Kurth, Ernestas Sirka, Johannes Hartl, Markus Ralser
medRxiv 2021.12.03.21267253; doi: https://doi.org/10.1101/2021.12.03.21267253
Subject Area
Subject Areas
- Addiction Medicine (334)
- Allergy and Immunology (657)
- Anesthesia (177)
- Cardiovascular Medicine (2561)
- Dermatology (217)
- Emergency Medicine (389)
- Epidemiology (12064)
- Forensic Medicine (10)
- Gastroenterology (741)
- Genetic and Genomic Medicine (3978)
- Geriatric Medicine (375)
- Health Economics (666)
- Health Informatics (2567)
- Health Policy (991)
- Hematology (357)
- HIV/AIDS (823)
- Medical Education (394)
- Medical Ethics (106)
- Nephrology (421)
- Neurology (3742)
- Nursing (206)
- Nutrition (558)
- Oncology (1946)
- Ophthalmology (565)
- Orthopedics (233)
- Otolaryngology (299)
- Pain Medicine (246)
- Palliative Medicine (72)
- Pathology (469)
- Pediatrics (1087)
- Primary Care Research (442)
- Public and Global Health (6406)
- Radiology and Imaging (1354)
- Respiratory Medicine (857)
- Rheumatology (393)
- Sports Medicine (336)
- Surgery (430)
- Toxicology (51)
- Transplantation (184)
- Urology (161)